• Explore /
  • Poster
  • / Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <em>BRAF</em> V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.

Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.

Abstract Video & Slides Poster

Authors

Darren Hargrave

Darren R. Hargrave

Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, United Kingdom

Darren R. Hargrave , Keita Terashima , Junichi Hara , Uwe R. Kordes , Santhosh A. Upadhyaya , Felix Sahm , Eric Bouffet , Roger J. Packer , Olaf Witt , Lali Sandalic , Agnieszka Kieloch , Mark W. Russo , Kenneth J. Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

NCT02684058

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2009)

DOI

10.1200/JCO.2022.40.16_suppl.2009

Abstract #

2009

Poster Bd #

347

Abstract Disclosures

Similar Posters

First Author: L Elizabeth Budde

First Author: Jonathan W. Goldman

First Author: Vivek Subbiah

First Author: Junji Furuse